Freedom of Information Request	FOI 22-105	15th March 2022

Question 1.
How many patients were treated by your Trust in the last 3 months with the following drugs:
The Health Board is unable to provide information on the number of patients treated with specific drugs. However, please find below the quantities dispensed, across Health Board pharmacies for the period December 2021 – February 2022:

Adalimumab (Amgevita)	Adalimumab (Humira)	Adalimumab (Hyrimoz)	Adalimumab (Idacio)	Adalimumab (Imraldi)
1360 x 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack 12 x 40 mg in 0.8mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	136 x 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack 26 x 40 mg in 0.4mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	None	None	154 x 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack

Question 2.
Of the patients treated with Humira in the last 3 months, how many were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)?
If possible, please provide new patients number by:

Last 3 Months

New Humira patients – all departments	New Humira patients – rheumatology	New Humira patients – dermatology	New Humira patients – gastroenterology
Not available	Not available	Not available	<5

Where less than five (5) patients have been identified, Section 40 of the Freedom of Information Act 2000 has been applied as the Health Board cannot provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test

Please note where it is stated the information is not available: The Health Board systems do not currently capture this information and would have to review every patient record to determine this. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take more than 18 hours to review the record of each patient.

Question 3.
Of the patients treated with any Adalimumab Biosimilar (Amgevita, Hyrimioz, Idacio, Imraldi etc) in the last 3 months, how many patients were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)?

If possible, provide new patients numbers by department:

Last 3 Months

New Adalimumab Biosimilar patients – all departments	New Adalimumab Biosimilar patients – rheumatology	New Adalimumab Biosimilar patients – dermatology	New Adalimumab Biosimilar patients – gastroenterology
Not available	Not available	Not available	Not available

Please refer to Q1 for quantities for this period and Q2 regarding figures not available.